Stoke Therapeutics Stock Today
| STOK Stock | USD 11.31 0.30 2.58% |
Performance0 of 100
| Odds Of DistressLess than 23
|
Stoke Therapeutics is selling for 11.31 as of the 21st of November 2024. This is a 2.58 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 11.08. Stoke Therapeutics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Stoke Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of May 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of June 2019 | Category Healthcare | Classification Health Care |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases in the United States. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. The company has 52.97 M outstanding shares of which 6.7 M shares are at this time shorted by private and institutional investors with about 13.69 trading days to cover. More on Stoke Therapeutics
Moving together with Stoke Stock
Moving against Stoke Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Stoke Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsStoke Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Stoke Therapeutics' financial leverage. It provides some insight into what part of Stoke Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stoke Therapeutics (STOK) is traded on NASDAQ Exchange in USA. It is located in 45 Wiggins Avenue, Bedford, MA, United States, 01730 and employs 110 people. Stoke Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 599.06 M. Stoke Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 52.97 M outstanding shares of which 6.7 M shares are at this time shorted by private and institutional investors with about 13.69 trading days to cover.
Stoke Therapeutics currently holds about 275.63 M in cash with (81.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99.
Check Stoke Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Stoke Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Stoke Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Stoke Therapeutics. Please pay attention to any change in the institutional holdings of Stoke Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Stoke Ownership Details
Stoke Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Assenagon Asset Management Sa | 2024-09-30 | 1.3 M | |
| Franklin Resources Inc | 2024-06-30 | 1.2 M | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 1.2 M | |
| Geode Capital Management, Llc | 2024-06-30 | 794.2 K | |
| Granahan Investment Management Inc.. | 2024-06-30 | 598.4 K | |
| Mpm Oncology Impact Management Lp | 2024-09-30 | 479.5 K | |
| Amvescap Plc. | 2024-06-30 | 437.1 K | |
| Cormorant Asset Management, Llc | 2024-06-30 | 427.2 K | |
| Northern Trust Corp | 2024-09-30 | 339.2 K | |
| Skorpios Trust | 2024-09-30 | 8.9 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 7 M |
Stoke Therapeutics Historical Income Statement
Stoke Stock Against Markets
Stoke Therapeutics Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Jonathan JD | Corporate Counsel | Profile | |
| Shamim MS | Chief Officer | Profile | |
| FACC MD | Chief Officer | Profile | |
| Joan Wood | Chief Officer | Profile | |
| Dawn Kalmar | Chief Officer | Profile | |
| Huw Nash | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.328 | Quarterly Revenue Growth 0.479 | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.